4DMedical Statistics
Total Valuation
4DMedical has a market cap or net worth of 78.86 million. The enterprise value is 71.61 million.
| Market Cap | 78.86M |
| Enterprise Value | 71.61M |
Important Dates
The next estimated earnings date is Friday, August 29, 2025.
| Earnings Date | Aug 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 465.52M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +46.00% |
| Shares Change (QoQ) | +67.40% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 377.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 21.76 |
| PB Ratio | 2.13 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.93 |
| EV / Sales | 18.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.81 |
Financial Position
The company has a current ratio of 1.03, with a Debt / Equity ratio of 0.08.
| Current Ratio | 1.03 |
| Quick Ratio | 0.88 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.16 |
| Interest Coverage | -169.85 |
Financial Efficiency
Return on equity (ROE) is -52.37% and return on invested capital (ROIC) is -35.74%.
| Return on Equity (ROE) | -52.37% |
| Return on Assets (ROA) | -23.32% |
| Return on Invested Capital (ROIC) | -35.74% |
| Return on Capital Employed (ROCE) | -57.35% |
| Revenue Per Employee | 24,997 |
| Profits Per Employee | -168,753 |
| Employee Count | 145 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0.35 |
Taxes
In the past 12 months, 4DMedical has paid 6,075 in taxes.
| Income Tax | 6,075 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.41% in the last 52 weeks. The beta is 1.40, so 4DMedical's price volatility has been higher than the market average.
| Beta (5Y) | 1.40 |
| 52-Week Price Change | -38.41% |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 24.27 |
| Average Volume (20 Days) | 12,707 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, 4DMedical had revenue of 3.62 million and -24.47 million in losses. Loss per share was -0.06.
| Revenue | 3.62M |
| Gross Profit | 3.39M |
| Operating Income | -28.37M |
| Pretax Income | -24.46M |
| Net Income | -24.47M |
| EBITDA | -27.95M |
| EBIT | -28.37M |
| Loss Per Share | -0.06 |
Balance Sheet
The company has 9.87 million in cash and 2.98 million in debt, giving a net cash position of 6.89 million.
| Cash & Cash Equivalents | 9.87M |
| Total Debt | 2.98M |
| Net Cash | 6.89M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 37.05M |
| Book Value Per Share | 0.09 |
| Working Capital | 390,773 |
Cash Flow
In the last 12 months, operating cash flow was -18.74 million and capital expenditures -59,428, giving a free cash flow of -18.80 million.
| Operating Cash Flow | -18.74M |
| Capital Expenditures | -59,428 |
| Free Cash Flow | -18.80M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 93.60% |
| Operating Margin | -782.83% |
| Pretax Margin | -674.92% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
4DMedical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -46.00% |
| Shareholder Yield | n/a |
| Earnings Yield | -31.03% |
| FCF Yield | -23.83% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
4DMedical has an Altman Z-Score of -0.46 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.46 |
| Piotroski F-Score | 2 |